Abstract
The biotechnology industry is a major growth area in the global healthcare
market, one upon which many companies are placing their hopes. Due to
developments in monoclonal antibodies, genomics and proteomics - amongst
others - the biotechnology market has experienced great expansion since its
emergence during the 1970' s. The leading healthcare biotechnology company,
Amgen, is now amongst the largest pharmaceutical companies in the world, with
other healthcare biotech companies catching up. The global biotech drug market
was worth over $75bn in 2007, with double-figure growth noticeably higher that
that of the overall pharmaceutical market. Our new report - Top-10 Biotech
Companies - Market Outlook, 2008-2023 - will help you to understand those
developments and their significance. That report provides valuable commercial
information on this exciting industry that no healthcare company should ignore.
Over the period 2008 to 2023, visiongain foresees the healthcare
biotechnological market continuing its strong growth, with exciting new
developments both technologically and commercially. Increased R&D efforts,
shorter approval times and innovative new treatments are aiding market growth.
However, the two major threats the healthcare biotechnology sector faces in
the coming years are the increasing threat of biogenerics and the difficulty
in acquiring capital. Strategic partnerships will continue to be important to
biotechnological drug development. There remain significant unmet needs in
this market, with great opportunities for companies that can develop safer and
better-targeted treatments.
Top-10 Biotech Companies - Market Outlook, 2008-2023 examines the product
portfolios of the leading companies critically, with in-depth analysis,
especially market forecasting and qualitative analysis of market drivers and
restraints. The result is a comprehensive market-based report with detailed
analysis and informed opinion.
Why you should buy this report:
In particular, Top-10 Biotech Companies - Market Outlook, 2008-2023
concentrates on the following essential aspects of the healthcare biotech
market:
- Achievements and aspirations of global healthcare biotechnology
- Detailed sales forecasts from 2008-2023 for the sector, leading biotech
companies and their main products
- Issues affecting the sector
- Discussion of drivers and opportunities
- Discussion of restraints and threats
- Detailed analyses of the top-10 healthcare biotech companies from 2008
onwards
- Salient pipeline developments in biotechnology and their implications for
the future.
In 2007, the global revenues generated by the top-10 biotech companies
exceeded $45bn. Amgen, Genentech and UCB are good examples of leading
companies that have experienced strong sales growth in recent years. Principal
drugs developed and marketed by the leading companies include Aranesp,
Mabthera and Keppra, each with blockbuster sales. Moreover, pipelines of the
leading biotech companies remain strong.
The leading healthcare biotechnology companies will continue to make strong
inroads into the overall global pharma industry and market in the years ahead,
with rising stars competing too. Do you know how sales of leading biotech
companies will develop over the coming years? Do you know the prospects for
other biotech organisations? Visiongain concludes that there will be
increasing reliance on biological drugs as time goes by, especially for
recalcitrant diseases with significant unmet needs. The commercial and
technological opportunities for greater personalisation of medicine through
biotechnology are very exciting. Certainly, the commercial opportunities for
dynamic healthcare biotech companies are significant. The development of
more-personalised medicine promising greater efficacy and safety -
particularly in cancer treatment - is a major commercial hope. By purchasing
this report, you will be better prepared to appreciate those major
developments in the global pharmaceutical market.
| 
View Cart
